Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumor
Clinical trial register · United States · industry-sponsored

Advanced Solid Tumor Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
Texas 87 California 67 Florida 57 New York 50 Michigan 43
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines11 Daiichi Sankyo7 OncoC4, Inc.5 TORL Biotherapeutics, LLC5 Eli Lilly and Company4
State
Texas87 California67 Florida57 New York50 Michigan43
All 42 states
Target enrolment
to

Advanced Solid Tumor trials in the USA

144 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
IntraAb, Inc.
Phase 1/2
60
California
2027-01-01
Not yet open
PharmaMar
Phase 1/2
231
Nebraska, Texas
2026-11-12
Recruiting
OncoC4, Inc.
Phase 1
20
New York, Pennsylvania, Texas
2026-08-10
Recruiting
Arvinas Inc.
Phase 1/2
499
North Carolina, Texas, Virginia
2026-07-29
By invitation
Gotistobart Long Term Extension (LTE) Study
NCT07659379Advanced Solid Tumor
DrugGotistobart
OncoC4, Inc.
Phase 3
20
Texas
2026-07-28
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
Strand Therapeutics Inc.
Phase 1/2
220
Arizona, Massachusetts, Tennessee
2026-06-30
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
NCT06887348Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Replimune, Inc.
Observational
50
California
2025-12-12
Recruiting
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
BeOne Medicines
Phase 1
86
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
BeOne Medicines
Phase 1
63
Texas, Virginia
2025-11-10
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Connecticut, New York, Texas
2025-10-10
Recruiting
Daiichi Sankyo
Phase 1
192
Florida, Rhode Island, Texas, Virginia
2025-10-02
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
Gilead Sciences
Phase 1
476
Massachusetts, Texas, Virginia
2025-08-28
Recruiting
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Recruiting
OBI Pharma, Inc
Phase 1/2
147
California, Texas
2025-08-04
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
FBD Biologics Limited
Phase 1
50
South Carolina
2025-04-02
Recruiting
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Recruiting
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Florida, Pennsylvania, South Dakota, Texas, Washington
2025-03-18
Active, closed
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1
234
Florida, Virginia
2025-02-10
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
Recruiting
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Recruiting
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Recruiting
BeOne Medicines
Phase 1
168
California, Connecticut, Minnesota, Texas, Washington, Wisconsin
2024-12-09
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Massachusetts, New York, Texas
2024-11-08
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
BeOne Medicines
Phase 1
153
New Jersey, Texas, Virginia, Wisconsin
2024-10-18
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
NCT06525298Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
DrugsTrastuzumab deruxtecan·Olaparib
Eisbach Bio GmbH
Phase 1/2
144
Texas
2024-09-09
Active, closed
TransCode Therapeutics
Phase 1/2
16
Texas, Utah, Virginia
2024-09-05
Recruiting
7 Hills Pharma, LLC
Phase 1/2
126
Colorado, Florida, New Hampshire, Rhode Island, Texas
2024-08-23
Recruiting
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
New York, Texas
2024-08-07
Recruiting
SW-682 in Advanced Solid Tumors
NCT06251310Advanced Solid Tumor, Mesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 1
186
Arizona, California, Ohio, Oregon, Texas
2024-07-31
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Recruiting
Aprea Therapeutics
Phase 1
90
Ohio, Texas, Virginia
2024-06-13
Active, closed
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Recruiting
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Florida, Utah
2024-06-05
Active, closed
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500Advanced Solid Tumor
Quanta Therapeutics
Phase 1
240
Michigan, North Carolina, Texas, Utah
2024-05-30
Recruiting
Strand Therapeutics Inc.
Phase 1/2
108
Arizona, California, Ohio, Pennsylvania, Texas, Utah
2024-05-03
Recruiting
SOTIO Biotech AG
Phase 1
40
Texas
2024-05-01
Recruiting
BeOne Medicines
Phase 1
308
California, Colorado, Florida, Maryland, Ohio
2024-04-12
Active, closed
D2M Biotherapeutics Inc.
Phase 1
160
Texas
2024-04-09
Recruiting
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Recruiting
Synnovation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Active, closed
Daiichi Sankyo
Phase 1
210
California, Florida, Hawaii, Illinois, Massachusetts, New York, North Carolina, Ohio
2024-02-22
Recruiting
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
DrugsTolododekin alfa·Cemiplimab
Ankyra Therapeutics, Inc
Phase 1
97
Maryland, Massachusetts, Oregon, Pennsylvania
2024-01-19
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Arizona, California, Florida, Missouri, Texas, Washington
2024-01-18
Recruiting
Fate Therapeutics
Phase 1
351
Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York
2024-01-05
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Recruiting
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Recruiting
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Arizona, California, Colorado, Florida, Illinois, Minnesota, New York, Ohio
2023-10-26
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
Volastra Therapeutics, Inc.
Phase 1/2
200
California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York
2023-10-18
Recruiting
FBD Biologics Limited
Phase 1
80
Florida, North Carolina, South Carolina, Texas
2023-10-02
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Recruiting
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
AMT-116 in Patients With Advanced Solid Tumors
NCT05725291Advanced Solid Tumor
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1
80
Colorado, Texas
2023-07-25
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
DrugsOlaparib·Ipilimumab
Lantern Pharma Inc.
Phase 1/2
64
Arkansas, Indiana, Kentucky, Maryland, Pennsylvania, Texas, Utah
2023-06-09
Recruiting
GI Innovation, Inc.
Phase 1/2
358
Arizona, Florida, Minnesota, New York, Ohio
2023-05-30
Recruiting
Daiichi Sankyo
Phase 1
128
Florida, Rhode Island, Utah, Virginia
2023-05-30
Recruiting
XTX301 in Patients With Advanced Solid Tumors
NCT05684965Advanced Solid Tumor
Xilio Development, Inc.
Phase 1/2
358
California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas
2023-05-11
Recruiting
PharmaMar
Phase 1
125
Texas
2023-04-28
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
DrugPYX-201
Pyxis Oncology, Inc
Phase 1
330
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2023-03-14
Recruiting
Lantern Pharma Inc.
Phase 1
110
Utah
2023-01-03
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
DrugsCHS-114·Toripalimab
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Recruiting
Aadi Bioscience, Inc.
Phase 1
28
Texas, Utah
2022-11-23
Active, closed
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
DrugsModified FOLFIRINOX·Dabrafenib·Pembrolizumab
Immuneering Corporation
Phase 1/2
209
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New York
2022-10-31
Recruiting
Oncomatryx Biopharma S.L.
Phase 1
150
Massachusetts
2022-10-20
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Active, closed
Nectin Therapeutics Ltd
Phase 1
90
California, Louisiana, Texas
2022-09-01
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Indiana, Texas, Washington
2022-08-25
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Michigan, Nevada
2022-07-19
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Georgia, Kentucky, New York
2022-07-12
Recruiting
Peel Therapeutics Inc
Phase 1
65
Arizona, California, North Carolina, Pennsylvania, Rhode Island, Texas, Utah, Virginia
2022-07-11
Active, closed
Glenmark Specialty S.A.
Phase 1
320
North Carolina, Wisconsin
2022-06-28
Active, closed
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
California, Colorado, District of Columbia, Massachusetts, Michigan, Missouri, New Mexico, New York
2022-05-25
Active, closed
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
NCT05352750Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Sonnet BioTherapeutics
Phase 1
42
California
2022-04-20
Recruiting
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1
39
Colorado, Florida, Ohio, Texas, Virginia
2022-03-31
Recruiting
A Study in Patients With Advanced Cancers
NCT05320588Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
DrugsKeytruda·Pembrolizumab
BiOneCure Therapeutics Inc.
Phase 1/2
332
Texas, Virginia
2022-03-25
Recruiting
Impact Therapeutics, Inc.
Phase 1/2
61
New Jersey, New York, South Carolina, Texas
2022-02-11
Active, closed
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT05156866Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLC
Phase 1
163
California, Indiana, Missouri, Texas
2022-02-02
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin
Synthekine
Phase 1/2
364
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts
2022-01-25
Active, closed
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
NCT05159440Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLC
Phase 1
70
California, Indiana, Missouri
2022-01-20
Active, closed
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
California, Illinois, Kentucky, Massachusetts, New Jersey, New York, North Carolina, Ohio
2022-01-11
Recruiting
TiumBio Co., Ltd.
Phase 1/2
240
Texas
2021-12-02
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
DrugTORL-1-23
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Active, closed
BicycleTx Limited
Phase 1/2
200
Iowa, New York, Ohio, Pennsylvania, Texas, Virginia
2021-11-02
Active, closed
Cullinan Therapeutics Inc.
Phase 1
440
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina
2021-10-29
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
New Jersey, New York, South Carolina, Virginia
2021-09-27
Recruiting
Senhwa Biosciences, Inc.
Phase 1
52
California, Florida, Massachusetts, New York, Ohio, Pennsylvania
2021-09-08
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
DrugsKeytruda·Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2
115
California, Florida, Georgia, Michigan, Texas
2021-08-27
Active, closed
Gilead Sciences
Phase 1
304
California, Connecticut, Massachusetts, Tennessee, Texas, Wisconsin
2021-08-18
Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
DrugsLenvatinib·Keytruda·Pembrolizumab
GI Innovation, Inc.
Phase 1/2
317
New York, North Carolina
2021-08-02
Recruiting
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166Advanced Solid Tumor, Metastatic Breast Cancer
DrugBTX-A51
Edgewood Oncology Inc.
Phase 1
112
Florida, Ohio, Tennessee, Texas
2021-06-07
Recruiting
Debiopharm International SA
Phase 1
464
California, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2021-04-30
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 2
141
California, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Missouri, New York
2021-04-22
Recruiting
ABL Bio, Inc.
Phase 1
100
California, Colorado, Texas
2021-04-01
Active, closed
Replimune, Inc.
Phase 1
123
Iowa, Pennsylvania, Texas
2020-12-29
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, New York
2020-10-29
Active, closed
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
DrugsDSP107·Atezolizumab
Kahr Medical
Phase 1/2
125
California, Colorado, Florida, Indiana, Kansas, Pennsylvania
2020-10-07
Active, closed
Mural Oncology, Inc
Phase 1/2
78
Michigan, Texas, Utah, Virginia
2020-09-30
Active, closed
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
DrugsGotistobart·Taxotere·Docetaxel·Keytruda
OncoC4, Inc.
Phase 1/2
733
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky
2020-09-16
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Arizona, Florida, Minnesota, Texas
2020-09-08
Active, closed
Daiichi Sankyo
Phase 1/2
247
Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey, New York, Tennessee
2019-11-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
California, Colorado, Illinois, Massachusetts, Michigan, Missouri, Ohio, Texas
2019-09-05
Rows per page Showing 1–144 of 144
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/advanced-solid-tumor

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 144 of those studies listing the condition Advanced Solid Tumor.

How many Advanced Solid Tumor trials are recruiting in the US?

102 of the 144 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 38 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumor), 144 studies
PhaseStudiesRecruitingShare
Phase 1846058.3%
Phase 1/2553938.2%
Phase 2322.1%
Observational110.7%
Phase 3100.7%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumor)
Lead sponsorStudiesRecruiting
BeOne Medicines1111
Daiichi Sankyo74
OncoC4, Inc.53
TORL Biotherapeutics, LLC51
Eli Lilly and Company42
EMD Serono Research & Development Institute, Inc.32
MediLink Therapeutics (Suzhou) Co., Ltd.33
BioNTech SE22
Clasp Therapeutics, Inc.21
Coherus Oncology, Inc.21

Top states

Top states (Advanced Solid Tumor), by number of studies with a site there
StateStudies
Texas87
California67
Florida57
New York50
Michigan43
Massachusetts41
Ohio31
Tennessee27
Colorado26
Missouri26
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.